Related Experiment Videos
Familial nonmedullary thyroid cancer
1Endocine Surgical Unit, University of California, San Francisco/Mount Zion Medical Center, 94143-1674, USA.
Current Treatment Options in Oncology
|June 14, 2002
Summary
Familial nonmedullary thyroid cancer is more aggressive and affects younger patients. Treatment includes total thyroidectomy, lymph node dissection, radioactive iodine ablation, and thyroid hormone suppression to manage this aggressive cancer.
Area of Science:
- Oncology
- Genetics
- Endocrinology
Background:
- Familial nonmedullary thyroid cancer (FNMTC) presents more aggressively than sporadic forms.
- FNMTC typically affects younger individuals and is characterized by multi-focal and bilateral tumors, predominantly papillary or Hürthle cell types.
Purpose of the Study:
- To outline optimal management strategies for familial nonmedullary thyroid cancer.
- To emphasize the importance of aggressive surgical and adjuvant therapies to reduce recurrence and improve outcomes.
Main Methods:
- Surgical recommendations include total thyroidectomy and ipsilateral central neck dissection.
- Postoperative management involves radioactive iodine (RAI) ablation and thyroid hormone suppression therapy.
- Management of metastatic disease and consideration of redifferentiation therapy are discussed.
Main Results:
- FNMTC exhibits higher aggressiveness, affecting younger patients with multi-focal/bilateral disease.
- High recurrence rates (44%) necessitate thorough surgical evaluation and adjuvant therapies.
- Prophylactic RAI and TSH suppression are key components of postoperative management.
Conclusions:
- Total thyroidectomy and careful lymph node dissection are crucial for FNMTC management.
- Postoperative RAI ablation and TSH suppression are recommended to minimize recurrence risk.
- Early detection, prevention, and targeted gene therapy hold future promise for FNMTC.